her2-negative
Entity, reached from Hormuz.
- Evidence
- 44 documents · 13 separate publishers
- Standing
- A name from our starting list; its record is kept up to date automatically from coverage
- Time
- first seen 23 Apr 2026, last seen 6 Oct 2026
- Measured
- 48% of mentions say something specific about it; the rest only name it
- As of
- 10 Oct 2026
Where this comes from
- Frontiers Precision Oncology · 2026-10-06 · Integrated CDK4/6 inhibitor resistance and primary-metastatic discordance in hormone receptor-positive/HER2-negative metastatic breast cancer: a translatio… (opens the source in a new tab)
- FDA D.I.S.C.O. (Drug Info Soundcast in Clinical · 2026-09-18 · FDA approves imlunestrant in combination with abemaciclib for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast can… (opens the source in a new tab)
- Annals of Oncology · 2026-09-09 · Sustained benefit of adjuvant olaparib in women with germline BRCA1- and BRCA2- -associated high-risk HER2-negative early breast cancer: Updated results from the Oly… (opens the source in a new tab)
- FDA · 2026-09-05 · FDA grants accelerated approval to camizestrant with a CDK4/6 inhibitor for ESR1-Mutated HR-positive, HER2-negative locally advanced or metastatic breast cancer (opens the source in a new tab)
- The ASCO Post · 2026-09-04 · Phase III OPTIMA Trial: Many Patients With ER-Positive, HER2-Negative Breast Cancer May Be Able to Avoid Chemotherapy (opens the source in a new tab)
- FDA Drug News · 2026-07-15 · [APPROVAL] FDA approves gedatolisib with fulvestrant, with or without palbociclib, for HR-positive, HER2-negative locally advanced or metastatic breast cancer (opens the source in a new tab)
- FDA Drug News · 2026-05-03 · [APPROVAL] FDA approves vepdegestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer (opens the source in a new tab)
Links from here: not yet read.
What is claimed about it
Situations it is named in
Who it moves with
- co-mentioned with her2 (44 documents)seen together
- co-mentioned with breast cancer (40 documents)seen together
- co-mentioned with fda (25 documents)seen together
- co-mentioned with immunotherapy (16 documents)seen together
- co-mentioned with etcamah (15 documents)seen together
- co-mentioned with ctdna (15 documents)seen together
- co-mentioned with ai (14 documents)seen together
- co-mentioned with astrazeneca (12 documents)seen together
- co-mentioned with lung cancer (11 documents)seen together
- co-mentioned with asco (10 documents)seen together